The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Renosen Pharmaceuticals Pvt Ltd
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Renosen Pharmaceuticals Pvt Ltd, part of the promoter group of Senores Pharmaceuticals, disclosed an open-market purchase of 1,000 equity shares on August 21, 2025. After the acquisition, Renosen's holding rose marginally from 27,05,219 shares (5.87%) to 27,06,219 shares (5.88%) of Senores Pharmaceuticals. The total equity share capital of Senores Pharmaceuticals remains unchanged at 4,60,53,588 shares of Rs. 10 each. The disclosure was filed under Regulation 29(2) of SEBI's SAST Regulations, 2011. The change in holding is negligible at 0.002%.
This is a very minor open-market purchase by a promoter-group entity with virtually no impact on the stock price or shareholder value. It signals continued promoter confidence but the scale is too small to be meaningful.